Effects of Senolytic Drugs on Human Stem-Like Cells: Preclinical Findings

Synopsis

Senolytic drugs are believed to target and remove senescent cells, potentially rejuvenating tissues and improving health and lifespan in aging models. This study tested four senolytic compounds—ABT-263 (navitoclax), quercetin, nicotinamide riboside, and danazol—during the long-term growth of human mesenchymal stromal cells (MSCs) until they reached replicative senescence. The effects were measured using markers such as senescence-associated beta-galactosidase (SA-β-gal), telomere shortening, and DNA methylation changes linked to aging. Among the drugs tested, only ABT-263 showed a moderate ability to reduce senescent cells, indicated by decreased SA-β-gal staining. However, none of the compounds, including ABT-263, affected the total number of cell divisions, telomere length, or epigenetic aging markers. These results suggest that while ABT-263 has some senolytic activity in human MSCs, it does not reverse cellular aging signs. More effective senolytic drugs are needed to realize their potential in regenerative medicine.

Journal

Stem Cell Research & Therapy